CGON 36.76 CG Oncology, Inc. Common stock
| Range: | 25.77-50.23 | Vol Avg: | 739078 | Last Div: | 0 | Changes: | 1.61 |
| Beta: | 0 | Cap: | 2.42B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Jan 01 1970 | Empoloyees: | 61 | ||
| CUSIP: | CIK: | 0001991792 | ISIN: | US1569441009 | Country: | ||
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Stock Details
CGON 75
H.C. Wainwright Reiterates Buy Rating on CG Oncology (CGON)
Andres Maldonado·Tue Sep 17 2024
H.C. Wainwright
CGON 52
Goldman Sachs Reiterates Buy Rating on CG Oncology (CGON)
Corinne Johnson·Mon Sep 16 2024
Goldman Sachs
CGON 50
CG Oncology upgraded to Buy from Neutral at Goldman Sachs
Corinne Johnson·Mon May 13 2024
Goldman Sachs
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow